In today’s session Bristol-Myers Squibb Co (BMY) registered an unusually high (531) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the March, 2017 call, expecting serious BMY increase. With 531 contracts traded and 49734 open interest for the Mar, 17 contract, it seems this is a quite bullish bet. The option with symbol: BMY170317C00057500 closed last at: $1.02 or 12.8% down. About 4.35 million shares traded hands. Bristol-Myers Squibb Co (NYSE:BMY) has declined 22.43% since April 5, 2016 and is downtrending. It has underperformed by 24.39% the S&P500.
Bristol-Myers Squibb Co (NYSE:BMY) Ratings Coverage
Out of 16 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 5 rate it a “Buy”, 3 “Sell”, while 8 “Hold”. This means 31% are positive. $80 is the highest target while $52 is the lowest. The $68.90 average target is 31.19% above today’s ($52.52) stock price. Bristol-Myers Squibb Company has been the topic of 34 analyst reports since July 28, 2015 according to StockzIntelligence Inc. The stock has “Sell” rating given by Societe Generale on Wednesday, April 6. The firm has “Market Perform” rating by BMO Capital Markets given on Monday, January 25. Citigroup maintained the shares of BMY in a report on Tuesday, September 20 with “Buy” rating. On Monday, May 23 the stock rating was initiated by Hilliard Lyons with “Neutral”. The firm has “Underweight” rating given on Friday, December 18 by Atlantic Securities. The firm has “Hold” rating given on Tuesday, June 14 by Jefferies. Barclays Capital maintained it with “Equal Weight” rating and $75 target price in Friday, April 29 report. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Underweight” rating by Piper Jaffray on Monday, August 24. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Hold” rating by Berenberg on Thursday, August 11. The firm earned “Hold” rating on Thursday, July 14 by Jefferies.
According to Zacks Investment Research, “Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.”
Insitutional Activity: The institutional sentiment increased to 0.94 in 2016 Q2. Its up 0.01, from 0.93 in 2016Q1. The ratio is positive, as 47 funds sold all Bristol-Myers Squibb Co shares owned while 542 reduced positions. 84 funds bought stakes while 472 increased positions. They now own 1.19 billion shares or 3.56% less from 1.23 billion shares in 2016Q1.
Gillespie Robinson And Grimm Inc holds 5,121 shares or 0.06% of its portfolio. Blackrock Lc last reported 3.64M shares in the company. Meeder Asset Inc, a Ohio-based fund reported 51,093 shares. Moreover, Cacti Asset Mngmt Ltd Liability Corp has 0.26% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 32,680 shares. Planning owns 29,784 shares or 0.17% of their US portfolio. Accredited, a Minnesota-based fund reported 16,432 shares. Stephens Ar has invested 0.44% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Bryn Mawr last reported 162,852 shares in the company. Meag Munich Ergo Kapitalanlagegesellschaft Mbh accumulated 94,882 shares or 0.63% of the stock. Crestpoint Capital Management Ltd Liability Com has 12,800 shares for 0.5% of their US portfolio. Hikari Pwr Ltd last reported 0.19% of its portfolio in the stock. Grassi Investment has 1.57% invested in the company for 112,762 shares. The California-based Integrated Wealth Counsel Ltd Llc has invested 0.63% in Bristol-Myers Squibb Co (NYSE:BMY). Independent accumulated 51,000 shares or 1.82% of the stock. Lawson Kroeker Invest Mngmt Ne reported 3,600 shares or 0.09% of all its holdings.
Insider Transactions: Since May 16, 2016, the stock had 0 insider purchases, and 7 sales for $9.25 million net activity. Caldarella Joseph C had sold 3,519 shares worth $255,004. 30,201 shares with value of $2.14 million were sold by Bancroft Charles A on Friday, May 20. On Wednesday, September 7 ANDREOTTI LAMBERTO sold $1.23 million worth of the stock or 21,600 shares. Shares for $859,219 were sold by Elicker John E on Tuesday, June 14.
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has a market cap of $87.77 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 26.16 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.
BMY Company Profile
Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
More important recent Bristol-Myers Squibb Co (NYSE:BMY) news were published by: Profitconfidential.com which released: “Bristol-Myers Squibb Co: THIS Will Influence Where BMY Stock Goes Next” on October 25, 2016, also Fool.com published article titled: “CheckMate Again for Bristol-Myers Squibb Co. As Shares Dip 10%”, Nasdaq.com published: “Earnings Reaction History: Bristol Myers Squibb Co, 40.0% Follow-Through …” on October 27, 2016. More interesting news about Bristol-Myers Squibb Co (NYSE:BMY) was released by: Fool.com and their article: “Why Bristol-Myers Squibb, Myriad Genetics, and Twilio Slumped Today” with publication date: October 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.